✦ LIBER ✦

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

✍ Scribed by Michinori Ogura; Toshiki Uchida; Masafumi Taniwaki; Kiyoshi Ando; Takashi Watanabe; Masanobu Kasai; Yosuke Matsumoto; Daisuke Shimizu; Yoshiaki Ogawa; Ken Ohmachi; Hiroki Yokoyama; Kensei Tobinai; the Japanese Bendamustine Lymphoma Study Group

Book ID: 108586791
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 174 KB
Volume: 101
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2010.01633.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicenter phase II study of bendamusti

Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

✍ Ken Ohmachi; Kiyoshi Ando; Michinori Ogura; Toshiki Uchida; Kuniaki Itoh; Nobuko 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB

Feasibility and pharmacokinetic study of

Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin’s lymphoma

✍ Michinori Ogura; Kiyoshi Ando; Masafumi Taniwaki; Takashi Watanabe; Toshiki Uchi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

Phase I trial of fludarabine, bortezomib

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

✍ Paul M. Barr; Pingfu Fu; Hillard M. Lazarus; Nancy Horvath; Stanton L. Gerson; O 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

A multicentre phase II clinical experien

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

✍ Owen A. O’Connor; Carol Portlock; Craig Moskowitz; David Straus; Paul Hamlin; Mi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

Bendamustine is effective therapy in pat

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma : Results from a Multicenter Study

✍ Brad S. Kahl; Nancy L. Bartlett; John P. Leonard; Ling Chen; Kristen Ganjoo; Mic 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

Phase II study of oral fludarabine in co

Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma

✍ Kensei Tobinai; Ken-ichi Ishizawa; Michinori Ogura; Kuniaki Itoh; Yasuo Morishim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 955 KB